Adaptive Biotechnologies and Flatiron Health Integrate clonoSEQ MRD Test into OncoEMR®

What You Should Know:  – Adaptive Biotechnologies Corporation and Flatiron Health today announced the integration of Adaptive’s clonoSEQ® test for measurable residual disease (MRD) assessment in lymphoid malignancies into OncoEMR®, Flatiron’s cloud-based Electronic Medical Record (EMR) platform.  – The integration aims to simplify and accelerate ac...

• Published date: 01-07-2025 01:10 PM